Heparin-binding protein improves prediction of severe sepsis in the emergency department
© Linder et al.; licensee BioMed Central Ltd. 2013
Published: 5 November 2013
The early identification of risk of developing severe sepsis in patients with suspected infection remains a difficult challenge. We hypothesized that an elevated plasma level of heparin-binding protein (HBP), a neutrophil-secreted mediator of vascular leakage, would be a predictor of delayed clinical deterioration and progressive organ dysfunction in emergency department (ED) sepsis patients.
Materials and methods
A prospective, multicenter study in Sweden and the US was conducted of 763 patients presenting to an ED with a suspected infection and signs of systemic inflammation. Based on recorded clinical and laboratory parameters and final diagnoses, patients were classified into various groups depending on the severity of the infection and inflammatory response. Plasma levels of HBP were measured and compared with levels of other standard sepsis biomarkers including procalcitonin, lactate, WBC, and C-reactive protein.
The final diagnoses were severe sepsis with organ failure in 338 patients, nonsevere sepsis without organ failure in 340 patients, and no infection in 85 patients. One-hundred and forty-three patients (19%) presented without signs of severe sepsis, but developed delayed circulatory failure and/or organ dysfunction within 72 hours of enrolment. In this patient group, an elevated HBP level could predict the delayed development of severe sepsis with an AUC value of 0.86. Elevated HBP levels (>30 ng/ml) were found in 80% of the patients and elevated procalcitonin levels (>0.5 ng/ml) were detected in 59%, 10.5 hours (median) before developing severe sepsis.
Detection of elevated plasma-HBP levels may help to provide an early risk-stratification of patients with suspected infections in the ED. An elevated HBP level was independently able to predict delayed clinical deterioration to overt shock or severe sepsis with organ failure.
This project was supported in part by Axis-Shield Diagnostics and the Swedish Government Funds for Clinical Research (ALF), the University Hospital, Lund, Sweden.
Clinical trial number
ClinicalTrials.gov NCT01392508 (the IMPRESSED study).
Potential conflicts of interests
AL, BC, and PÅ are listed as inventors on a patent filed by Hansa Medical AB.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.